rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NTLA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Intellia Therapeutics (NTLA), Why Is It Back In The Spotlight?
      Nov 17Yahoo FinanceNTLA
      Intellia at Jefferies global healthcare conference: launch and pipeline in focus
      Nov 17Investing.comNTLAJEF
      Intellia stock price target maintained at $30 by Citizens on HAE data
      Nov 13Investing.comNTLA
      Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears
      Nov 12Yahoo FinanceNTLA
      Intellia presents lonvo-z data at allergy conference
      Nov 12Investing.comNTLA
      Intellia Therapeutics (NTLA) Stock Could Look Stretched On Phase 3 Trial Progress

      Intellia Therapeutics has had a bruising long run for shareholders, with the stock still down sharply over the past five years even after a positive year to date. That leaves a clear question about how its current US$11.35 share price lines up with the sales it is generating today. With fresh milestones in gene editing and late stage programs back in focus, investors are increasingly asking whether the revenue base behind Intellia now justifies where the stock trades. Over the last 5 years,...

      Nov 7Yahoo FinanceNTLA
      Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision

      Intellia Therapeutics approaches a FDA decision in March 2027 for lonvo-z. Discover more on the NTLA's program and why a positive outcome is anticipated.

      Nov 6Seeking AlphaNTLA
      Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
      Nov 6Yahoo FinanceNTLA
      Intellia Therapeutics Inc earnings missed by $0.11, revenue fell short of estimates
      Nov 5Investing.comNTLA
      Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
      Nov 5Yahoo FinanceNTLA
      Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
      Nov 5Yahoo FinanceNTLA
      Intellia earnings loom: Can CRISPR biotech stabilize revenue?
      Nov 4Investing.comNTLA
      Intellia completes enrollment in phase 3 trial for ATTRv-PN therapy
      Nov 4Investing.comNTLA
      Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
      Nov 3Yahoo FinanceNTLA
      Intellia Therapeutics shares may move 3.8% on earnings release
      Oct 30Investing.comNTLA
      Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

      Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals Poster presentations to include patient perspective about life after lonvo-z treatmentIntellia to host investor webcast on Thursday, November 12 at 10 a.m. ET CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolution

      Oct 29Yahoo FinanceNTLA
      The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
      Oct 21Yahoo FinanceBBIOBIIBNTLA
      Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations Advance
      Oct 18Yahoo FinanceNTLA
      Intellia Therapeutics names Jing Marantz as chief medical officer
      Oct 13Investing.comNTLA
      Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
      Oct 9Yahoo FinanceNTLA
      Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target
      Oct 6Yahoo FinanceNTLA
      Cathie Wood's Ark Invest weekly recap: loads up on Nvidia, Intellia; pares AMD (ARKK:BATS)

      Cathie Wood’s Ark Invest stepped up its semiconductor, biotechnology and technology exposure during the week ended October 2,

      Oct 5Seeking AlphaAMDNTLANVDAARKK
      Intellia Therapeutics Q2 2026 Earnings Call Transcript - Intellia Therapeutics (NASDAQ:NTLA)

      Intellia Therapeutics (NASDAQ:NTLA) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call

      Oct 5BenzingaNTLA
      Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 2Yahoo FinanceNTLA
      Cathie Wood’s ARK buys Intellia stock, sells Alphabet shares
      Oct 1Investing.comGOOGNTLA
      Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
      Sep 29BarchartNTLA
      Could This Cathie Wood Stock Soar in 2027? | The Motley Fool

      This biotech has grabbed plenty of headlines recently.

      Sep 27The Motley FoolNTLA
      Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA)

      Intellia update: Claude AI flags a gene-editing setup but can’t replicate it. Lonvo-z targets a 2027 launch; Nex-z enrollment rebounds. Click for more on NTLA stock.

      Sep 27Seeking AlphaNTLA
      Gene editing stocks fall on Anthropic’s CRISPR-like discovery

      Gene editing stocks fall as Anthropic’s (ANTHRO) AI model Claude discovers a new enzyme system similar to the gene-editing tool CRISPR. Read more here.

      Sep 23Seeking AlphaCRSPLENZNTLA
      Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy

      Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. The FDA does not plan to convene an advisory committee, with review supported by positive Phase 3 data and multiple global designations. The FDA's Priority Review of lonvo-z for hereditary angioedema is a key regulatory event to weigh...

      Sep 22Yahoo FinanceNTLA
      Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
      Sep 19Yahoo FinanceNTLA
      Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?

      NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

      Sep 18Yahoo FinanceTESTNTLA
      Intellia at Morgan Stanley conference: launch path and cash runway
      Sep 14Investing.comNTLAMS
      Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia
      Sep 12Investing.comNTLATWST
      Intellia: Lonvo-Z Does Not Need To Dominate HAE For The Stock To Work (NASDAQ:NTLA)

      Intellia Therapeutics (NTLA) has spent years being valued as a gene-editing science project.

      Sep 11Seeking AlphaNTLA
      Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings
      Sep 11Investing.comNTLA
      Exclusive BAC Article: Intellia Therapeutics; Lonzo-V PDUFA March 10th 2027, Nex-Z Ph3 Trials ATTR Back On Track, And Catalysts (NASDAQ:NTLA)

      I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Intellia Therapeutics (NTLA).

      Sep 10Seeking AlphaNTLA
      Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?

      Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement. The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing […]

      Sep 10Yahoo FinanceNTLA
      Intellia’s Lonvo-z Gains FDA Priority Review for HAE

      Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailNTLA
      FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

      NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

      Sep 9Yahoo FinanceNTLA
      H.C. Wainwright reiterates Intellia stock rating on FDA review progress
      Sep 9Investing.comNTLA
      Citizens reiterates Intellia stock rating on FDA priority review
      Sep 9Investing.comNTLA
      Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

      Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

      Sep 8The Globe and MailNTLA
      Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform

      The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.

      Sep 8Yahoo FinanceNTLA
      Why is Intellia Therapeutics stock rallying today?
      Sep 8Investing.comNTLA
      Intellia stock rises on FDA priority review (NTLA:NASDAQ)

      Intellia Therapeutics (NTLA) stock gains on FDA priority review for lonvo-z, a gene editing therapy for a rare condition called hereditary angioedema. Read more here.

      Sep 8Seeking AlphaNTLA
      Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z

      Intellia Therapeutics (NASDAQ:NTLA) shares rose 8% on Tuesday after the U. S.

      Sep 8Yahoo FinanceNTLA
      Intellia Therapeutics stock jumps on FDA priority review
      Sep 8Investing.comNTLA
      Citizens reiterates Intellia stock rating on HAE opportunity potential
      Sep 8Investing.comNTLA
      Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema

      Intellia Therapeutics (NTLA) said Tuesday that the US Food and Drug Administration has accepted the

      Sep 8Yahoo FinanceNTLA

      This is the newest page. Registered accounts read further back.